NCT04686682View on ClinicalTrials.gov

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

May 7, 2021

Primary Completion Date

January 31, 2024

Study Completion Date

September 30, 2024

Conditions
NSCLCSCLCCRPCESCCOvarian CarcinomaAMLMFMalignant Tumor
Interventions
DRUG

JAB-8263

Variable dose, orally Q2D with 28 days each cycle

DRUG

JAB-8263

RP2D dose, orally Q2D with 28 days each cycle

Trial Locations (1)

300020

RECRUITING

Tianjin, Tianjin

Sponsors
All Listed Sponsors
lead

Jacobio Pharmaceuticals Co., Ltd.

INDUSTRY